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Open repair may carry a higher complication rate when com-
plex anastomoses are required deep in the pelvis or graft
limbs must be extended to the femoral level. There have
been several reports of endovascular repair under these cir-
cumstances with the use of aorto-uni-iliac (A-I) grafts com-
bined with femoral-femoral bypass.1-4 An A-I system was
specifically designed by EVT/Guidant to deal with this tech-
nically more demanding clinical problem. This report pre-
sents the results of the prospective multicenter
EVT/Guidant A-I trial with 1-year follow-up carried out
under an Investigative Device Exemption approved by the
Food and Drug Administration (FDA) and compares this
experience with the tube (T) and bifurcated (B) endograft
series previously reported to the FDA.
MATERIAL AND METHODS
The EVT/Guidant A-I system consists of three pri-
mary components: a sheath to facilitate introduction of
Patients with infrarenal abdominal aortic aneurysms
(AAA) that involve the iliac arteries present a more complex
challenge for either conventional or endovascular repair.
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Objective: Our objective was to present the results of the multicenter EVT/Guidant aorto-uni-iliac trial and to compare them
with the tube, bifurcated graft, and open control series in regard to patient demographics, medical comorbidity, 30-day mor-
bidity/mortality, and outcome at 1 year.
Methods: One hundred twenty-one patients not eligible for tube or bifurcated endografts were entered into the aorto-uni-iliac
trial (A-I). These were compared with 153 patients in a tube (T) group, 268 patients in a bifurcated endograft (BI) group, and
111 patients in an open control (C) group. All data were audited and independently analyzed for presentation to the Food and
Drug Administration.
Results: Group demographics were similar with the following exceptions. Aneurysm diameter was significantly less in the T
group (51.2 mm) but similar for the A-I (57 mm), BI (54.6 mm), and C (55.6 mm) groups (P < .001). There were more male
patients in all endograft groups (A-I 92.6%, BI 89.5%, T 85.6% vs 76.6% for C, P = .002). Peripheral arterial occlusion was
present more frequently in the A-I group (25.6% vs 13.8% BI, 10.5% T, and 10.8% C, P = .003). However, no differences were
found in mean age, incidence of coronary artery disease, and American Society of Anesthesiologists III/IV classification.
Implantation was achieved in 94.2% of the A-I group, 90.3% of the BI group, and 92% of the T group. No significant differ-
ence was seen in the operative mortality rate (4.2% A-I, 2.6% BI, O% T, 2.7% C). Postoperative cardiac complications were sim-
ilar for the A-I (22%) and C (20.7%) groups but significantly less for the BI and T groups (13.4% and 10.5%, P = .019), whereas
pulmonary problems were significantly reduced in all endograft groups (A-I 11.9%, BI 10.1%, and T 7.2% vs 22.5% for C, P =
.002). Transient renal dysfunction occurred in 6.8% of the A-I group and 8.2% of the BI group but in only 3.3% of the T group
and 1.8% of the C group (P = .028). Operating time was significantly longer for the A-I group than for the BI, T, or C groups
(258 minutes vs 156, 179, and 174 minutes). Median blood loss, intensive care unit use, and hospital stays were markedly and
significantly reduced in all endograft groups compared with the control group. The incidences of type I endoleak at 1 year were
2.4% A-I, 2.3% BI, and 3.8% T, and no ruptures occurred in any of the patients treated with endografts. No femoral-femoral
graft thromboses occurred in the A-I group.
Conclusion: Despite the fact that patients with combined aortic and iliac aneurysms have a more complex repair requirement
and have an increased rate of comorbidity, the results are competitive with endovascular repair of aortic aneurysm by tube
and bifurcated graft systems and are associated with a lower morbidity than open operation. (J Vasc Surg 2001;33:S11-20.)
wires, catheters, and the delivery system; the A-I delivery
catheter containing the endograft; and an endosoc
occluder to close the contralateral common iliac artery.
The EVT/Guidant A-I graft is made of lightweight
woven polyester. It is a unit body construction. The graft
body segment tapers to a single graft limb. The graft limb is
crimped to permit angle change without kinking. Proximal
and distal graft fixation is achieved by self-expanding attach-
ment frames made of elgeloy that incorporate hooks placed
at intervals around their circumference. When the attach-
ment system is deployed, it spontaneously expands to the
vessel wall. The hooks are seated into the arterial wall by
inflation of a balloon that is intrinsic to the delivery system.
The graft, balloon, and deployment mechanism are pack-
aged in a 23F (o.d.) coaxial catheter delivery system that is
covered with a retractable jacket. Deployment of the proxi-
mal and distal attachment systems is easily controlled by
release mechanisms incorporated in the handle of a delivery
catheter.
The endosoc occluder consists of a short length of
polyester tubing that is closed at one end and contains an
intrinsic self-expanding attachment system complete with
radial hooks and is packaged in a 16F catheter. When
deployed to occlude the contralateral iliac artery, it
becomes a “blind sac,” thereby preventing reflux of blood
into the aortoiliac aneurysm while flow is preserved to the
hypogastric artery.
Patient selection. Patients who were not candidates by
protocol for either the tube or bifurcation endografts
because of the presence of iliac aneurysm were considered
for the A-I system (121). A proximal neck at least 15 mm
in length and no greater than 26 mm in diameter is
required. Excessive calcification, thrombus, and severe
angulation of the proximal neck were considered relative
contraindications for endovascular repair. The distal end of
the graft is deployed in the common iliac artery if anatomi-
cally feasible. If deployment in the external iliac artery is
required, preliminary coil occlusion of the hypogastric
artery, if patent, must be performed to prevent retrograde
endoleak from that source. The anatomic requirement for
deployment of the endosoc occluder was a minimum 1-cm
segment of contralateral common iliac artery proximal to
the hypogastric artery that did not exceed 13 mm in diam-
eter. When the distal iliac neck was too short or too wide,
coil embolization was used to occlude the common iliac
aneurysm to preserve a patent hypogastric artery. The
patients included in this protocol were required to be
acceptable candidates for open operation in case conversion
was required and to have a life expectancy of at least 2 years.
Technique of implantation. The procedure is per-
formed with the patient under general or epidural anes-
thesia in an operating department or an interventional
suite with operating department capability. If hypogastric
artery occlusion is required on the endograft insertion
side, it is best to accomplish this step in advance, although
it was sometimes performed at the time of implantation.
Both femoral arteries are surgically exposed, and an
aortogram is obtained to mark the renal arteries and the
aortic bifurcation and to reconfirm graft length with an
angioscale catheter. After systemic heparinization is per-
formed, a longitudinal arteriotomy is made in the ipsilat-
eral femoral artery to introduce the subsequent sheath and
catheter and to provide the inflow site for the femoral-
femoral bypass. Under fluoroscopic control, the catheter
delivery system is advanced through a previously placed
sheath over a stiff guidewire to the level of the renal arter-
ies. The attachment hooks are aligned with the renal
artery marker, and the proximal attachment system is
deployed and secured in place by balloon inflation.
Thereafter, the distal attachment system is deployed and
also secured with the intrinsic balloon. The catheter deliv-
ery system is exchanged for a high-pressure balloon angio-
plasty catheter, which is sequentially dilated along the
entire length of the graft limb to fully expand the endo-
graft and dilate any atheromatous lesions that might cause
extrinsic graft compression. The guidewire and sheath are
then removed, and the arteriotomy is used for the proxi-
mal anastomosis of the femoral-femoral graft. The graft is
then clamped distal to the anastomosis, and flow is
restored to the ipsilateral leg.
A limited angiogram of the contralateral iliac artery is
obtained to define and mark the origin of the hypogastric
artery. Through a longitudinal arteriotomy, the endosoc
occluder catheter system is passed over a wire. The
endosoc occluder is deployed in the distal common iliac
artery while a common channel is maintained between the
external and internal iliac arteries. The endosoc is seated
with the balloon intrinsic to that catheter. The endosoc
delivery catheter and sheath are removed, and the distal
femoral-femoral anastomosis is performed at the con-
tralateral femoral arteriotomy site. An aortogram is then
obtained to check for endoleak, compression, or kinking
of the graft limb, anastomotic integrity of the femoral-
femoral bypass, and documentation of the filling of the
contralateral hypogastric artery.
Follow-up protocol. At or around the time of hospi-
tal discharge, at 6 months, and yearly thereafter, all
patients who undergo the endograft procedure receive a
physical examination, measurement of ankle/brachial
indexes, an abdominal ultrasound examination of the
endograft, femoral-femoral bypass for endoleak or graft
dysfunction, plane films of the abdomen to visualize the
graft and attachment systems, and a contrast-enhanced
computed tomography scan for aneurysm sac size or evi-
dence of endoleak. If an endoleak was noted at discharge,
a computed tomography scan was repeated at 3 months.
Patients in the control group were similarly monitored,
with the exception of plane abdominal films.
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The imaging studies were independently reviewed by
a core laboratory at the Cleveland Clinic.
All data were recorded on case report forms in com-
pliance with an FDA-approved protocol for investigation
and were audited for accuracy and completeness.
Control group. The control group (111 patients) for
the A-I system was the same group of patients that was
used to compare the safety and effectiveness of the T and
B systems. They were treated by standard aneurysm resec-
tion and were managed concurrently with the endograft
patients. They were physiologically similar in regard to risk
factors but were excluded from endograft therapy because
of anatomic features that precluded deployment of a tube
endograft. As a result, 85% of the patients in the control
group were able to undergo an open tube graft repair, and
only 15% required bifurcation grafts at the time of open
surgery. Because these patients did not have anatomically
complex aneurysms, it would be expected that the results
of standard open repair might be better, or at least no
worse, than those of a group of patients with concomitant
aortic and iliac aneurysm. Therefore a greater burden was
placed on the endograft group to show safety and effec-
tiveness compared with the less complex group of patients
in the control group. The use of the single control group
for all three groups was approved by the FDA.
Statistical analysis. All analyses that involved a
dichotomous response (eg, presence or absence of medical
comorbidities, 30-day morbidity and mortality, or an
endoleak) were analyzed with Fischer exact test. A one-way
analysis of variance was used to test for equal mean ages
across treatment groups. Kruskal-Wallis tests were used to
test for equality across treatment groups with respect to
anesthesia risk level, length of hospital stay, operation time,
blood loss, and baseline, discharge, 6-month, and 12-
month aneurysm sizes. Mortality at 12 months was ana-
lyzed by a log-rank test to test for equality of survival
curves across treatment groups. An exact Kruskal-Wallis
test was used to test the null hypotheses that levels of
change involving aneurysm diameters (decrease, no
change, or increase) were equal across treatment groups.
RESULTS
From November 14, 1996, to December 2, 1998,
121 patients underwent attempted implantation of the
EVT/Guidant A-I endograft system at 15 investigational
sites, T endograft placement was attempted in 153
patients at 20 centers, and B endografts were attempted in
268 patients at 18 centers under protocols approved by
the FDA. One hundred eleven patients receiving standard
open repair served as a control group for the three endo-
graft study groups (Appendix 1).
The patients were well matched with regard to age.
There was a preponderance of male sex in the A-I and B
groups compared with the control group. An average
aneurysm diameter of 51.2 mm in the T group was signifi-
cantly smaller than the 57 mm diameter in the A-I group,
but the latter was not different compared with the B endo-
grafts and the control series. The A-I group had a signifi-
cantly higher incidence of previous myocardial infarction and
cardiac arrhythmia and a significantly higher incidence of
peripheral arterial occlusive disease. Otherwise, the groups
appeared to be well matched (Table I).
Table I. Demographic and medical comorbidity
A-I (121) Tube (153) Bifurcated (268) Control (111) 
No.(%) No.(%) No.(%) No.(%) P value
Age (mean) 73.2 73.8 72.7 71.6 .107
Male sex (%) 92.6* 85.6 89.5* 76.6 .002
Aortic aneurysm diameter (mean) (mm) 57 51.2* 54.6 55.6 <.001
CAD 79 (65.3) 85 (55.6) 165 (61.6) 68 (61.3) .418
MI 56 (46.3) 45 (29.4) 105 (39.2) 43 (38.7) .036
Arrhythmia 45 (37.8) 40 (26.1) 89 (33.2) 21 (18.9) .007
Valvular heart disease 14 (11.6) 20 (13.1) 32 (11.9) 10 (9) .790
CHF 21 (17.4) 18 (11.8) 35 (13.1) 8 (7.2) .131
Cerebrovascular disease 15 (12.4) 29 (19) 32 (11.9) 15 (13.5) .246
Hypertension 76 (62.8) 91 (59.5) 166 (61.9) 79 (71.2) .243
PVD 31 (25.6) 16 (10.5) 37 (13.8) 12 (10.8) .003
COPD 48 (39.7) 43 (28.1) 77 (28.7) 33 (29.7) .143
Smoking 109 (90.8) 117 (76.5) 217 (81) 100 (90.1) .003
Diabetes 15 (12.4) 18 (11.8) 32 (11.9) 11 (9.9) .952
Renal insufficiency 6 (5) 9 (5.9) 18 (6.7) 5 (4.5) .865
Anesthesia risk
Class I 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.9) .354
Class II 16 (13.2) 27 (17.9) 36 (13.5) 14 (12.6)
Class III 86 (71.1) 103 (68.2) 175 (65.8) 79 (71.2)
Class IV 19 (15.7) 21 (13.9) 54 (20.3) 17 (15.3)
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive heart failure; PVD, peripheral vascular disease; COPD,
chronic obstructive pulmonary disease.
*Statistically significant difference from control.
Successful implantation occurred in 94.2% of the A-I
group, 92% of the T group, and 90% of the B group, with
no intergroup difference in the cause of failure. Unsuccessful
implants were converted to open repair at the time of origi-
nal operation. All three study groups had statistically signifi-
cant reduction in operative blood loss compared with the
control group. The A-I group operative time of 258.4 min-
utes was significantly longer than the other three. All three
endograft groups had a marked and statistically reduced inci-
dence of intensive care unit use compared with the control
group (38.6% A-I, 35.5% T, 39.1% B vs 96.3% c) and a sta-
tistically significant reduction in median hospital stay (3, 2,
and 3, respectively, vs 6) (Table II).
Table III summarizes the 30-day morbidity and mor-
tality rates. There was a slightly higher mortality rate in the
A-I group, which approached but did not achieve statisti-
cal significance compared with the others. A statistically
significant reduction occurred in respiratory complications
and bleeding complications among all three endograft
study groups compared with the control group. A higher
incidence of minor wound complications, transient renal
dysfunction, and wound hematoma was noted among the
endograft groups compared with the control group. The
incidence of postoperative cardiac complications in the A-I
group was equivalent to that in the control group but was
statistically higher than the incidence of cardiac complica-
tions among the T and B groups. Bowel complications
were primarily ileus, requiring nasogastric decompression.
No patient in any group required resection for ischemic
bowel.
To compare the overall measure of safety (risk) of the
experimental groups with regard to the control group, a
parameter called the Investigative Device Exemption com-
posite safety measure was devised in consultation with the
FDA. It includes all of the complications listed in Table III
(Appendix 2). The control group had the highest inci-
dence at 44.1%. There was a marked reduction in both the
T and B endograft groups at 19.6% and 28.7%, respec-
tively. Although the incidence was higher in the A-I group
(35.6%), it was statistically less than that in the control
group.
The mortality rates at 12 months including the 30-day
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Table II. Perioperative data
A-I (n=121) Tube (n=153) Bifurcated (n=268) Control (n=111) P value
Successful implant (%) 114 (94.2) 141 (92) 242 (90) 111 (100) .001
Blood loss (median) (cc) 400* 200* 300* 800 <.001
Mean (SD) 533.7 (509.5) 412.5 (789.4) 567.4 (813.8) 1051.8 (1042.3)
Operative time (mean) (min) 258.4 179.4 156.4 174.4 <.001
SD 76.7 82.9 92.5 59.2
Need for ICU (%) 38.6 35.5 39.1 96.3 .005
Hospital stay (median days) 3 2 3 6 <.001
Mean (SD) 5.4 (9.4) 3.2 (3.2) 4.3 (8.6) 7.5 (6.5)
ICU, Intensive care unit.
*Statistically significant difference from control.
Table III. Thirty-day morbidity/mortality
A-I Tube Bifurcated Control P value
Mortality (%) 4.2 0 2.6 2.7 .056
Investigative Device Exemption composite safety (risk) (%) 35.6 19.6 28.7 44.1 <.001
Respiratory (%) 11.9* 7.2* 10.1* 22.5 .002
Bleeding requiring transfusion (%) 15.3* 8.5* 15.7* 39.6 <.001
Cardiac (%) 22 10.5 13.4 20.7 .019
Bowel (%) 5.9 5.2 3.0 8.1 .160
Wound (%) 7.6 5.2 3.4 1.8 .134
Renal (%) 6.8 3.3 8.2 1.8 .038
DVT (%) 1.7 0.7 1.1 0.9 .904
Embolism (%) 1.7 3.9 3.0 0.9 .454
Hematoma (%) 8.5 10.5 9.3 1.8 .027
Impotence (%) 1.7 0 0 1.8 .028
Paraplegia/paraparesis (%) 0.8 0 0 0 .352
Prosthetic thrombosis (%) 1.7 0 2.6 0 .061
Pulmonary embolism (%) 0.8 0 0 0 .352
Stroke (%) 0.8 0 0.7 0.9 .691
DVT, Deep venous thrombosis.
*Statistically significant difference from control.
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mortality rate were not statistically different between any
group (Appendix 3). Most of the late deaths were due to
cardiac, pulmonary, or cancer-related causes. No device-
related deaths occurred.
Endoleaks in this series were limited to type I (attach-
ments site), type II (back flow from lumbar or inferior
mesenteric arteries), and those that could not be differen-
tiated between types I and II (indeterminate). Table IV
compares the overall and type I endoleak rates among the
three graft configurations as a function of time. No statis-
tically significant differences were seen in initial overall or
type I endoleak rates among the graft configurations, and
each showed a progressive fall in persistent endoleak rate
at both the 6- and 12-month follow-ups.
All configurations showed a statistically significant and
progressive reduction of sac diameter over time (Table V).
Table VI compares sac diameter change in patients with
type I endoleak with that in those with no endoleak. The
aneurysms either shrunk more than 5 mm or remained
unchanged irrespective of the presence or absence of type
I endoleak. It is noteworthy that no patients in the A-I
group had an increase in sac diameter, and no patient in
that group has required a late conversion to open repair.
One patient in the T group and two patients in the B
groups required late conversion because of sac enlarge-
ment. None of those patients had a surgical mortality.
Graft limb compromise resulting in either reduced
blood flow or graft limb occlusion occurred only in the A-
I and in the B series. Correction usually took the form of
balloon angioplasty, stent placement, or both. Overall,
30% of the aortoiliac configuration and 38% of the bifur-
cation graft configuration required some intervention to
correct problems with graft limb blood flow. Most of these
were identified and treated during the operation
(Appendix 4).
The ultimate benefit of any procedure designed to
treat patients with AAA including endovascular repair is
best measured by its ability to prevent aneurysm rupture.
To date, there have been no aneurysm ruptures in any of
the three endovascular groups.
Finally, the placement of a subcutaneous femoral-
femoral bypass, which is intrinsic to the A-I protocol, was
evaluated. Two patients had a graft infection, for an inci-
dence of 1.6%. These required explantation of the
femoral-femoral prosthesis. There was no instance of
femoral-femoral graft thrombosis.
DISCUSSION
The standard operative repair of AAA has proved to be
both effective and durable. Low morbidity and mortality
rates have been reported in centers of excellence.5-8
However, the risk of operation has been documented to
be considerably higher in several community- or popula-
tion-based reports.9-12 Major complications of open repair
occur in at least 15% to 30% of patients.13,14 Morbidity
and mortality rates increase substantially in elderly patients
or those patients with pulmonary, cardiac, or renal comor-
bidity.13,15 Therefore many patients at high risk are denied
aneurysm repair. The possibility that a less invasive
method for AAA treatment might reduce risk, pain, and
suffering and extend the opportunity for successful repair
to patients being currently denied operation has great
appeal.
The first clinical report of endovascular repair of AAA
with the use of a device assembled from currently available
components was reported by Parodi et al16 in 1991. The
first commercially available endoluminal prosthesis devel-
oped for investigational purposes was manufactured by
Endovascular Technologies, with the first successful clini-
cal implantation in February 1993.17 Since then, a variety
of devices have entered clinical investigation.18-23 We have
documented the 1-year results of the EVT/Guidant A-I
endograft and have compared the patient characteristics
and outcome parameters with those of the EVT/Guidant
tube and bifurcated endograft devices and of a control
group of patients undergoing standard open surgical
repair. Although the study is nonrandomized, it should be
emphasized that these were large, prospective, multicen-
ter, concurrent trials comparing closely matched groups of
patients who differed primarily in their aortoiliac anatomy.
Male sex predominance in the endograft groups likely
reflects the relatively large caliber (23F o.d.) of the
EVT/Guidant devices, which tended to eliminate some
women with associated small iliac or femoral vessels from
endoluminal treatment with this device. Patients treated
with A-I endografts were sicker, as indicated by a signifi-
cantly increased incidence of previous myocardial infarc-
tion, history of arrhythmia, and associated peripheral
arterial occlusive disease. Other comorbidities were well
matched across all treatment groups. Because these stud-
ies were done as a part of an FDA-approved protocol for
investigation, all data were collected prospectively, care-
fully monitored by specially trained clinical research asso-
Table IV. All endoleaks (type I – attachment site)
Discharge 6 Months 12 Months
Aortoiliac (%) 55.7 (7.6) 37.46.6 (6.9) 31.9 (2.9)
Tube (%) 44.4 (11.1) 25.2 (7.3) 25.0 (3.8)
Bifurcation (%) 48.4 (5.0) 40.5 (7.2) 31.3 (2.3)
P value .253 (.107) .003 (1.0) .508 (.908)
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ciates, and audited for accuracy. In addition, all imaging
data were critically reviewed by an independent clinical
research organization (core laboratory) at the Cleveland
Clinic.
The mortality rates did not differ significantly among
the endograft groups when compared with open repair,
primarily because the mortality rate in the control group
was so low (2.7%). Endograft repair was associated with a
statistically significant reduction in blood loss, blood
replacement, intensive care unit use, and hospital stay.
Overall, clinically important morbidity and mortality as
reflected by the Investigative Device Exemption compos-
ite safety (risk) measure were significantly less for all three
configurations of endoluminal repair device compared
with those of the open control group. Although there was
a trend toward higher morbidity and mortality in the A-I
group, this difference was not statistically significant but
probably reflected the fact that these patients had an asso-
ciated higher incidence of comorbidity and more extensive
aneurysm disease. Likewise, there was a trend toward a
higher 12-month mortality rate in the A-I group, but
again, these differences were not statistically significant
among the endograft groups when compared with the
control group.
Endovascular repair of AAA is associated with a new or
unique complication of endoleak. Endoleak has been
defined as a continuing contribution of some blood flow
to the aneurysm sac and has been categorized into four
types. Type I represents some blood flow that occurs
between the attachment site and the arterial wall, type II
is backflow from a lumbar or inferior mesenteric artery,
type III is primarily associated with modular endografts
and occurs with a modular disconnect but can also be a
tear in the stented portion of the fabric, and type IV rep-
resents increased porosity through the endograft fabric.24
Only type I and type II endoleaks have been associated
with the EVT/Guidant endografts. Of these, the type I
endoleak is believed to be the more serious. Although the
initial endoleak rate in this series appears to be high, this
is due in part to the fact that the imaging studies used for
endoleak involve both abdominal ultrasound scanning and
contrast computed tomography scan. If an endoleak was
thought to be possible by either study as reviewed by the
core laboratory, an endoleak was scored as positive. Some
investigators have reported that ultrasound studies are
overly sensitive and result in falsely elevated endoleak
rates, particularly type II endoleaks.25,26 Our endoleak
rates are not dissimilar from those reported in many other
series. For example, a meta-analysis of 23 publications
describing 1118 patients with successfully inserted trans-
femoral endografts documented an average endoleak rate
of 24%.27 In our series at least 50% of such endoleaks
spontaneously sealed over a 12-month interval, and AAA
sac diameters in such patients demonstrated a decrease in
size similar to that of those patients without endoleak.28,29
Furthermore the clinical significance of endoleak remains
uncertain and somewhat poorly understood.30,31 As illus-
trated by our data, only 3 (18.8%) of 16 patients with type
I endoleak had an increase of AAA maximum diameter at
12 months, and only 5 (7.2%) of 69 patients with type II
endoleaks had an increase in aneurysm size. Some investi-
gators believe that type II endoleaks, by far the most com-
mon in our series, are less likely to result in abdominal
aneurysm sac growth or rupture.32 Other authorities sug-
gest that AAA enlargement or rupture may well occur
without demonstrable endoleak, possibly as a result of
pressure transmission between the pulsating endograft and
thrombus (“endotension”).33,34 Thus endoleak per se may
be a poor marker for the subsequent risk of AAA enlarge-
ment or rupture.35,36 Nonetheless, aneurysm sac enlarge-
ment is a cause for concern. If the mechanism cannot be
corrected, it is recommended that conversion to open
repair be undertaken.
The goal of any treatment of AAA is to prevent expan-
sion and rupture. Our 1-year data in this regard show excel-
lent results. The overall mean AAA diameter decreased in all
treatment groups. AAA enlargement was observed in only
12 (4.1%) of 292 patients, and not a single incidence of
Table V. Aneurysm diameter (mean)
Discharge 6 Months 12 Months P value
Aortoiliac (mm) 54.3 51.3 47.7 <.001
Tube (mm) 48.9 45.6 44.1 <.001
Bifurcation (mm) 52.3 48.6 46.2 <.001
Table VI. Change in aneurysm diameter with no endoleak (type I endoleak) at 12 months
Decrease (>0.5 mm) No change Increase (>0.5 mm) P value
Aortoiliac (%) 60.9 (75.0) 39.1 (0.0) 0.0 (25.0) .574 (0.528)
Tube (%) 52.6 (33.3) 43.4 (33.3) 4.0 (33.3)
Bifurcation (%) 55.3 (50.0) 43.5 (50.0) 1.2 (0.0)
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AAA rupture has occurred in this series to date. In this
context the predicted annual rate of rupture of AAA in the
5.0 to 5.9 cm range, representative of patients in all three
endograft study groups in our series, would be anticipated
to be approximately 10%.37,38 At 1 year, only 3 (0.6%) of
197 of the patients in this report required conversion to
open repair. There have been no instances of migration or
structural failure to date.
The favorable experience reported from this series
suggests that the EVT/Guidant endograft design concept
may have a unique advantage in terms of long-term per-
formance.39,40 Their one-piece unit-body construction
combined with a nonsupported graft trunk and limbs and
unique hook attachment systems appears to obviate many
of the morphologic and structural problems reported in
other endograft devices. Problems reported with other
devices include endograft kinking, limb thrombosis, mod-
ular joint separation, and proximal or distal attachment
migration and dislodgment.41-46 The potential advantages
of the EVT/Guidant systems, however, come with some
disadvantages. These include a larger diameter delivery
system. The larger diameter is a consequence of the hook
attachment mechanism and the unit-body design. This
increased diameter may reduce the application of the
device in patients with small access arteries. It is also
acknowledged that the deployment procedure, particu-
larly of the bifurcated endograft, is more complex than
devices using the modular approach. Although the sup-
ported trunk and limbs of the EVT/Guidant device may
allow improved adaptability to late morphologic AAA sac
changes, it is also recognized that there is risk of limb
twisting, kinking, or compression that may require intra-
operative or postoperative adjunctive procedures such as
the placement of a stent in the graft limb.
The availability of different configurations of endografts
is clearly advantageous. Thus the use of the A-I system has
improved the applicability of endograft repair to those
patients with iliac aneurysmal disease. Recognized advan-
tages of this configuration include the relative simplicity of
the device and deployment without extensive intravascular
catheter maneuvers or manipulation, the absence of concern
regarding proper rotational status of the device, the lack of
modular joint connections with their potential liabilities,
and the fact that only one iliac artery need be suitable for
the delivery system insertion and stent-graft implantation.
The less stringent surgery requirements of A-I devices may
also facilitate use in more urgent clinical circumstances
including ruptured aneurysms, as reported by other
groups.47,48
Potential disadvantages of the A-I endografts are
related, principally, to the possible problems associated
with the femoral-femoral bypass component. These
include the risks of thrombosis, infection, or failure to pro-
vide retrograde flow to the contralateral hypogastric
artery. In our series there was no instance of femoral-
femoral graft thrombosis. There were, however, two
instances of crossover graft infection (1.6%). The excellent
patency rate reported in this series is almost certainly the
result of its use in patients with aneurysm disease and
good distal runoff, as opposed to the more common use
in patients with symptomatic peripheral arterial occlusive
disease.49,50
In summary, this report has demonstrated that
endovascular repair of AAA with all three configurations
of the EVT/Guidant endograft can achieve reliable AAA
exclusion with subsequent prevention of AAA expansion
or rupture. There is a high degree of clinical success in the
short term. Although long-term performance data are
clearly imperative, we believe that the results with mini-
mum 1-year follow-up are at least equal to those of con-
ventional open repair. Although not necessarily better
than standard surgical repair, such clinical equipoise makes
it appropriate to offer this method of repair with its less
invasive characteristics and benefits to properly selected
patients if it is their choice. More important, it offers a rea-
sonable solution for treatment of patients with AAA who
are at high risk for open repair and have been previously
denied the open operation.
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Appendix 1. Investigational sites and subject enrollment
Investigational site Aortoiliac group Tube group Bifurcated group Control group
Albany Medical College NA 0 NA 1
Cleveland Clinic NA 10 5 0
Dartmouth-Hitchcock 3 8 7 9
East Carolina University 7 NA 28 NA
Emory University Hospital 12 16 10 3
Henry Ford Hospital 3 7 NA 2
Hospital of the University of Pennsylvania 3 NA NA NA
Jobst Vascular Center NA 4 NA 4
Mayo Clinic NA 3 7 3
Massachusetts General Hospital 23 6 17 9
Miami Vascular Institute 6 4 25 1
Montefiore Medical Center 2 1 1 0
Northwestern Medical Center 1 4 10 6
New York University Medical Center NA 4 17 6
Ochsner Clinic 2 6 6 1
Sentara Norfolk General Hospital 9 9 12 7
St. Thomas/Vanderbilt 14 17 23 17
St. Vincent Hospital, Indianapolis 1 NA 4 NA
University of Colorado Medical Center NA 3 NA 3
UCLA 18 22 39 5
University of Pittsburgh 8 15 33 11
University of Utah Medical Center NA 5 7 14
Washington University Medical Center 12 9 18 9
N 121 153 268 111
Appendix 2. Investigative Device Exemption composite safety measure
To compare the overall measure of safety (risk) of the experimental groups with regard to the control group, a parameter called the
“Investigative Device Exemption composite safety measure” was devised in consultation with the FDA. Specifically, the Investigative
Device Exemption composite safety measure includes the following complications: severe procedural or postprocedural bleeding; severe
hematoma, coagulopathy, moderate or severe respiratory failure, moderate or severe atelectasis/pneumonia; pulmonary embolism; mod-
erate or severe myocardial infarction; congestive heart failure; arrhythmia requiring intervention; renal insufficiency; moderate or severe
wound infection; abdominal wound dehiscence; severe lymphatic problems including chylous ascites; bowel ischemia; adynamic ileus;
bowel obstruction; severe lower extremity ischemia as a result of embolism; moderate or severe arterial trauma; femoral-femoral bypass
graft thrombosis; amputation; moderate or severe stroke; deep venous thrombosis; paraplegia/paraparesis; impotence; aortoenteric fis-
tula; aortocaval fistula; aortic dissection; endograft prosthetics thrombosis; endograft prosthetic infection; femoral-femoral graft infec-
tion; and death.
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Appendix 4. Incidence and occurrence of treatment for
reduced graft limb blood flow up to 12 months
Aorto iliac Bifurcation 
(n = 114) (n = 242) P value
Intraoperative (%) 24 (21) 68 (28) .381
Postoperative (%) 8 (7) 22 (9)
Both (%) 2 (2) 3 (1)
Total (%) 34 (30) 93 (38)
Appendix 3. Twelve-month mortality
Interval ending 1 month 2 months 6 months 12 months P value
A-I .199
No. entered 118 113 113 108
No. events in interval 5 0 5 4
No. censored in interval 0 0 0 6
No. event free in interval 113 113 108 98
Mortality rate (%) 4.2 4.2 9.5 11.9
95% CI 0.6-7.9 0.6-7.9 3.4-13.5 5.9-18.0
Tube
No. entered 153 152 152 149
No. events in interval 0 0 3 6
No. censored in interval 1 0 0 8
No. event free in interval 152 152 149 135
Mortality rate (%) 0.0 0.0 2.0 6.0
95% CI — — 0.0-4.2 2.1-9.9
Bifurcated
No. entered 268 260 259 250
No. events in interval 7 1 7 4
No. censored in interval 1 0 2 47
No. event free in interval 260 259 250 199
Mortality rate (%) 2.6 3.0 5.6 7.1
95% CI 0.7-4.5 0.9-5.0 2.8-8.4 3.7-10.6
Control
No. entered 111 108 107 106
No. events in interval 3 1 1 1
No. censored in interval 0 0 0 5
No. event free in interval 108 107 106 100
Mortality rate (%) 2.7 3.6 4.5 5.4
95% CI 0.0-5.7 0.1-7.1 0.6-8.4 1.1-9.7
